<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
  • Menu
  • crown-logo-symbol-1-400x551

Find it Quickly

Get Started

Select the option that best describes what you are looking for

  • Services
  • Models
  • Scientific Information

Search Here For Services

Click Here to Start Over

Search Here For Models

Click Here to Start Over

Search Here For Scientific Information

Click Here to Start Over

In Vitro

Boost oncology drug discovery with XenoBase®, featuring the largest cell line selection and exclusive 3D organoid models. Benefit from OrganoidXplore™ and OmniScreen™ for rapid, in-depth analysis.

Learn More

In Vivo

Enhance drug development with our validated in vivo models, in vitro/ex vivo assays, and in silico modeling. Tailored solutions to optimize your candidates.

Learn More

Tissue

Experience ISO-certified biobanking quality. Access top biospecimens from a global clinical network, annotated by experts for precise research.

Learn More

Biomarkers and Bioanalysis

Leverage our global labs and 150+ scientists for fast, tailored project execution. Benefit from our expertise, cutting-edge tech, and validated workflows for reliable data outcomes.

Learn More

Data Science and Bioinformatics

Harness your data and discover biomarkers with our top bioinformatics expertise. Maximize data value and gain critical insights to accelerate drug discovery and elevate projects.

Learn More

KRAS

Accelerate innovative cancer treatments with our advanced models and precise drug screening for KRAS mutations, efficiently turning insights into clinical breakthroughs.

Learn More

EGFR

Advance translational pharmacology with our diverse pre-clinical models, robust assays, and data science-driven biomarker analysis, multi-omics, and spatial biology.

Learn More

Drug Resistance

Our suite integrates preclinical solutions, bioanalytical read-outs, and multi-omics to uncover drug resistance markers and expedite discovery with our unique four-step strategy.

Learn More

Patient Tissue

Enhance treatments with our human tumor and mouse models, including xenografts and organoids, for accurate cancer biology representation.

Learn More

Bioinformatics

Apply the most appropriate in silico framework to your pharmacology data or historical datasets to elevate your study design and analysis, and to improve your chances of clinical success.

Learn More

Biomarker Analysis

Integrate advanced statistics into your drug development projects to gain significant biological insight into your therapeutic candidate, with our expert team of bioinformaticians.

Learn More

CRISPR/Cas9

Accelerate your discoveries with our reliable CRISPR solutions. Our global CRISPR licenses cover an integrated drug discovery platform for in vitro and in vivo efficacy studies.

Learn More

Genomics

Rely on our experienced genomics services to deliver high quality, interpretable results using highly sensitive PCR-based, real-time PCR, and NGS technologies and advanced data analytics.

Learn More

In Vitro High Content Imaging

Gain more insights into tumor growth and disease progression by leveraging our 2D and 3D fluorescence optical imaging.

Learn More

Mass Spectrometry-based Proteomics

Next-generation ion mobility mass spectrometry (MS)-based proteomics services available globally to help meet your study needs.

Learn More

Ex Vivo Patient Tissue

Gain better insight into the phenotypic response of your therapeutic candidate in organoids and ex vivo patient tissue.

Learn More

Spatial Multi-Omics Analysis

Certified CRO services with NanoString GeoMx Digital Spatial Profiling.

Learn More

Biomarker Discovery

De-risk your drug development with early identification of candidate biomarkers and utilize our biomarker discovery services to optimize clinical trial design.

Learn More

DMPK Services

Rapidly evaluate your molecule’s pharmaceutical and safety properties with our in vivo drug metabolism and pharmacokinetic (DMPK) services to select the most robust drug formulations.

Learn More

Efficacy Testing

Explore how the novel HuGEMM™ and HuCELL™ platforms can assess the efficacy of your molecule and accelerate your immuno-oncology drug discovery programs.

Learn More

Laboratory Services

Employ cutting-edge multi-omics methods to obtain accurate and comprehensive data for optimal data-based decisions.

Learn More

Pharmacology & Bioanalytical Services

Leverage our suite of structural biology services including, recombinant protein expression and protein crystallography, and target validation services including RNAi.

Learn More

Screens

Find the most appropriate screen to accelerate your drug development: discover in vivo screens with MuScreen™ and in vitro cell line screening with OmniScreen™.

Learn More

Toxicology

Carry out safety pharmacology studies as standalone assessments or embedded within our overall toxicological profiling to assess cardiovascular, metabolic and renal/urinary systems.

Learn More

Our Company

Global CRO in California, USA offering preclinical and translational oncology platforms with high-quality in vivo, in vitro, and ex vivo models.

Learn More

Our Purpose

Learn more about the impact we make through our scientific talent, high-quality standards, and innovation.

Learn More

Our Responsibility

We build a sustainable future by supporting employee growth, fostering leadership, and exceeding customer needs. Our values focus on innovation, social responsibility, and community well-being.

Learn More

Meet Our Leadership Team

We build a sustainable future by fostering leadership, employee growth, and exceeding customer needs with innovation and social responsibility.

Learn More

Scientific Advisory Board

Our Scientific Advisory Board of experts shapes our strategy and ensures top scientific standards in research and development.

Learn More

News & Events

Stay updated with Crown Bioscience's latest news, achievements, and announcements. Check our schedule for upcoming events and plan your visit.

Learn More

Career Opportunities

Join us for a fast-paced career addressing life science needs with innovative technologies. Thrive in a respectful, growth-focused environment.

Learn More

Scientific Publications

Access our latest scientific research and peer-reviewed articles. Discover cutting-edge findings and insights driving innovation and excellence in bioscience.

Learn More

Resources

Discover valuable insights and curated materials to support your R&D efforts. Explore the latest trends, innovations, and expertly curated content in bioscience.

Learn More

Blogs

Explore our blogs for the latest insights, research breakthroughs, and industry trends. Stay educated with expert perspectives and in-depth articles driving innovation in bioscience.

Learn More

  • Platforms
  • Target Solutions
  • Technologies
  • Service Types

How to Detect, Characterize, and Evaluate CAR-Ts: Top 13 Questions

Dr. Rajendra KumariReview key questions on preclinical models and rare cell analysis technology for assessing CAR-T cell therapies from our recent webinar, answered by Dr. Rajendra Kumari, Global Head of Scientific Communication.

Target Identification and In Vitro Assays

Are You Able to Help with Identifying Targets for CAR-Ts?

The general approach for identifying targets for CAR-T cell therapies is to identify proteins/antigens uniquely expressed in targeted cancer cells, such as CD19 and ROR1. For example, ROR1 is expressed on chronic lymphocytic leukemia cells but not normal adult cells except for hematogones.

Exhaustive searches have been performed to screen such proteins based on expression profiles. Recent efforts have focused on conformational changes of proteins, even if the expression of such proteins is not cancer-specific. Both approaches can use either large-scale screening to filter down potential candidates experimentally, or computational methods to identify candidates based on genomic data.

So yes, we can take the computational approach as well, but the chance of finding novel targets is very small. We can, however, work with customers on the validation of their potential targets, both computationally and experimentally, particularly in mouse tumor models.

How Do you Check In Vitro for CAR-T Long Term Functionality?

T cell kill assays are performed to assess the efficacy or potency, or chemokine/cytokine release assays.

In Vivo CAR-T Models and Assays

How do you Determine the Numbers of CAR-T to be Injected? Does it Depend on the Target Antigen Expression Level?

For in vivo studies, the number of CAR-T is dependent on the target, expression levels, avidity/potency of CAR, and persistence, which can be assessed beforehand (e.g. in vitro, tolerability, PK studies).

What is the Best Assay for Monitoring CAR-T Cell Persistence Real-Time In Vivo?

You can track CAR-T persistence real-time by labeling with luciferase or fluorescent proteins (e.g. GFP, etc.).

What Sort of Models would be Suitable for CAR-NK Cell Therapies?

Similar to CAR-T, models expressing the relevant target.

Do You Use Fresh or Frozen CAR-Ts for a Large Screen using Multiple PDX Models?

You can use either fresh or frozen CAR-Ts. More coordination is required with fresh cells whereas it is easier with frozen cells. Ex vivo analysis also needs to be coordinated. However, this is very much dependent on the CAR-T production, amount available, and study location, which would drive the number of models. The number of models can also be influenced by the specific antigen and cancer type, as well as the breadth of models available.

What are Things to Consider When Assessing CAR-Ts in Immunocompetent Mice?

The mice need to be lympho-depleted with cyclophosphamide or low dose irradiation prior to CAR-T injection, in order to create space for the engrafted cells to expand.

What is the Best Assay for CAR-T Cell Exhaustion/Dysfunction in a Syngeneic Cancer Mouse Model?

You can assess exhaustion markers like PD-1, TIGIT, TIM-3, etc. and also check the cytokine/chemokine production and cytotoxicity ex vivo.

Do You See any Immunogenic Response with the Syngeneic Lines Expressing Human Tumor Associated Antigens?

It varies with the antigen and the cell line. We look at standard growth kinetics and clinical signs in mice to detect signs of immunogenic response. Most of the time the expression levels are low enough so there is no impact. In some cases, growth rate is slowed or there may be weight loss. In addition, we have worked quite a bit with syngeneic luciferase lines and see very little immunogenic response there. It makes sense that high levels of cell surface expression may enhance immunogenic response.

Organoids for CAR-T Cell Therapy Evaluation

Are you Developing any Organoids for CAR-T Evaluation?

Yes, through our collaboration with Hubrecht Organoid Technology (HUB) using their protocols, which originated from the Clevers lab. These models will include patient-derived organoids (PDO) from HUB and PDX-derived organoids (PDXO) generated from our PDX collection.

PDX are widely used for CAR-T studies but the throughput is challenging. The organoid platform will enable more models, with diverse expression levels of antigens, heterogeneity, and different cancer types using a lot less CAR-Ts in a higher throughput 384-well format.

There have been reports of organoids being used to look at colorectal cancer response to CAR-T and NK therapies (e.g. targeting EPCAM). We’re exploring co-culture methods with immune cells at the moment, but new technology and the assay conditions will need to be optimized to test CAR-Ts. The first platform to be offered is PDXO screening, with a diverse collection of cancer types with matched in vivo models.

Would 3D Models/Human Organoids help if No In Vivo Model is Satisfactory?

Organoids have the advantage over in vivo models in that human normal tissue can be cultured, enabling toxicity testing on normal human tissue which isn’t possible with xenograft systems or syngeneics.

Rare Cell Analysis Technology

Can You Look at CAR-T Phenotypes utilizing the Rare Cell Analysis Technology?

Yes, different phenotypes such as CD4+ vs CD8+ can be analyzed. The technology is potentially superior for cells like central memory cells, which may have a longer persistence compared to effector phenotypes associated with better efficacy.

Have You Used the Rare Cell Analysis Technology to Detect CTCs?

Yes, the technology has been used to detect CTC in PDX models, which was actually the original purpose. The platform was then extended for preclinical and clinical CAR-T detection to study the mechanism of response/relapse by correlating efficacy with penetrance.


Related Posts